ArticleBulletin of experimental biology and medicine2026
Protein Kinase C Blockers Do Not Reverse the Cardioprotective Effect of Probiotic Strains in Rats with a Systemic Inflammatory Response.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypothesis that protein kinase C (PKC) participates in the signaling stage of the cardioprotective response to the administration of probiotics was tested in experiments on male Wistar rats using a model of systemic inflammatory response syndrome (SIRS), which includes obesity and chemically induced colitis. To provide probiotic cardioprotective effects, Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12) were administered orally. PKC inhibitor chelerythrine at a dose of 0.5 mg/kg was administered intraperitoneally 20 min before the start of isolated Langendorff heart perfusion. Global ischemia (30 min) and reperfusion (90 min) were simulated, after which the size of the necrosis zone was histochemically determined. In the SIRS group, we observed a significant increase in leukocyte count and the size of the necrosis zone (by 39%; p < 0.05) in comparison with the control. In groups with probiotic correction and PKC + probiotic, the size of the necrosis zone was significantly lower than in the SIRS group. Administration of chelerythrine did not abolish the cardioprotective effect of probiotics. In the SIRS model, probiotic-induced cardioprotection is mediated by mechanisms that prevent ischemic/reperfusion damage that differ from the PKC pathway.
Indexed as
Identifiers
42530829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.